Lantern Pharma Inc. (NASDAQ: LTRN) has announced notable clinical observations from its Phase 2 HARMONIC™ clinical trial. A 70-year-old patient with advanced non-small cell lung cancer (NSCLC), who has never smoked, has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-of-care chemotherapy. This patient continues to show sustained survival benefits nearly two years after the treatment. LP-300, developed using Lantern's proprietary RADR® AI platform, is being evaluated for its therapeutic potential in never-smokers with advanced NSCLC who have progressed after treatment with tyrosine kinase inhibitors. Results from this study have already been presented, showing promise for LP-300 as a treatment option in this patient population.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.